Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

260
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
260
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

796
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
796
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

204
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
204
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

163
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
163
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

273
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
273

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Cardiac-Arterial Coupling After Cardiac Surgery for Aortic Valve Disease.

Reviews in cardiovascular medicine·2026
Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same author

Sex Differences in Clinical Outcomes and Loss of Life Expectancy After Aortic Valve Surgery for Infective Endocarditis: A SWEDEHEART Study.

Journal of the American Heart Association·2026
Same author

Oxylipin-mediated metabolic signatures of symbiosis homeostasis and thermal stress in a model sea anemone.

The ISME journal·2026
Same author

Ferroptosis promotes aortic stenosis through 5-lipoxygenase.

European heart journal·2026
Same author

LIPID MAPS: Powering discovery in lipidomics.

Science signaling·2026

Related Experiment Video

Updated: Dec 19, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.6K

Omega-3 Polyunsaturated Fatty Acids Decrease Aortic Valve Disease Through the Resolvin E1 and ChemR23 Axis.

Gonzalo Artiach1, Miguel Carracedo1, Oscar Plunde1

  • 1Department of Medicine (G.A., M.C., O.P., S.T., A.L.-F., H.A., M.B.), Karolinska Institutet, Stockholm, Sweden.

Circulation
|June 9, 2020
PubMed
Summary
This summary is machine-generated.

Omega-3 fatty acids (n-3 PUFAs) and their mediator resolvin E1 inhibit aortic valve stenosis (AVS) progression. Targeting this pathway may offer new therapeutic options for AVS.

Keywords:
calcification, physiologicfatty acids, omega-3heart valve diseasesinflammationlipids

More Related Videos

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.5K

Related Experiment Videos

Last Updated: Dec 19, 2025

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.6K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.5K

Area of Science:

  • Cardiovascular Biology
  • Lipidomics
  • Inflammation Research

Background:

  • Aortic valve stenosis (AVS) is the most common valvular heart disease, characterized by aortic valve thickening and calcification.
  • Omega-3 polyunsaturated fatty acids (n-3 PUFAs) show cardiovascular benefits, and are precursors to specialized proresolving mediators with anti-inflammatory properties.
  • The role of n-3 PUFAs and their derived mediators in AVS pathogenesis remains largely undetermined.

Purpose of the Study:

  • To investigate the role of n-3 PUFA-derived specialized proresolving mediators in the development of AVS.
  • To determine if resolvin E1 influences aortic valve calcification.

Main Methods:

  • Lipidomic and transcriptomic analyses of human aortic valves.
  • Utilized Apoe-/- mice and wire injury models for mechanistic studies.
  • Investigated the effects of endogenous n-3 PUFA synthesis and resolvin E1 receptor (ChemR23) activity.

Main Results:

  • n-3 PUFA incorporation was higher in noncalcified than calcified regions of human stenotic valves.
  • Resolvin E1 was dysregulated in calcified regions and inhibited calcification.
  • Mice with enhanced endogenous n-3 PUFA synthesis showed reduced valve calcification and improved cardiac function.
  • Blocking the resolvin E1 receptor abolished these beneficial effects.

Conclusions:

  • The n-3 PUFA-derived resolvin E1 and its receptor ChemR23 axis is crucial for inhibiting AVS progression.
  • This pathway represents a potential novel therapeutic target for AVS patients.